Table 1.

Serum CA-125 levels (U/mL) according to tumor pathology and menopausal status

Tumor pathologySerum CA-125, U/mL
All patients (N = 3,511)Premenopausal (N = 2,134)Postmenopausal (N = 1,377)
nMedian (IQR)RangenMedianRangenMedianRange
Benign2,56018 (11–39)1–40,1401,809201–40,140751152–13,510
Endometrioma71343 (23–89)2–3,500683444–3,50030332–844
Teratoma40213 (9–20)1–288345141–28857114–30
Simple cyst/parasalpingeal cyst28114 (10–20)4–512163154–512118124–220
Functional cyst11616 (10–25)2–360100162–36016145–37
Hydrosalpinx + salpingitis10019 (12–49)5–60788195–60712226–232
Peritoneal pseudocyst2116 (11–29)8–13718168–753238–137
Abscess4245 (20–123)1–1,01230611–800122811–1,012
Fibroma15218 (12–41)3–1,40956203–38296163–1,409
Serous cystadenoma42014 (10–21)2–780173143–381247152–780
Mucinous cystadenoma27015 (10–24)2–13,510133162–306137143–13,510
Rare benign4317 (11–38)5–40,14020257–40,14023145–32,56
Malignant951158 (35–610)2–38,161325804–18,0556262222–38,161
Borderline, stage I16429 (17–76)3–2,77989274–2,77975333–2,080
Borderline, stage II8165 (36–219)15–80735524–192518715–807
Borderline, stage III–IV14327 (32–942)5–12,82911565–7,86331,290499–12,829
Primary invasive, stage I13681 (25–289)2–5,62042415–3,25694952–5,620
Primary invasive, stage II47229 (57–907)11–6,0861312118–1,6863432811–6,086
Primary invasive, stage III334401 (160–1,183)7–38,1617737514–18,0552574287–38,161
Primary invasive, stage IV58725 (285–2,424)5–10,40013810132–10,400457045–7,360
Rare primary invasive7049 (18–210)4–1,18937586–1,18933364–814
Metastatic invasive12099 (25–333)5–4,67040737–859801325–4,670

Abbreviation: IQR, interquartile range.